Posted by Michael Wonder on 24 Apr 2023
Avidity Biosciences granted FDA fast track designation for AOC 1044 for treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping
24 April 2023 - Avidity Biosciences today announced that the US FDA has granted fast track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping (DMD44).
AOC 1044 is being assessed in the Phase 1/2 EXPLORE44 clinical trial for people living with DMD44 and is the first of multiple antibody oligonucleotide conjugates the company is developing for Duchenne muscular dystrophy.
